Literature DB >> 11083501

Inhibition of recombinant adeno-associated virus (rAAV) transduction by bronchial secretions from cystic fibrosis patients.

I Virella-Lowell1, A Poirier, K A Chesnut, M Brantly, T R Flotte.   

Abstract

The conducting airways are the primary target for gene transfer in cystic fibrosis (CF), yet the inflammation associated with CF lung disease could potentially pose a significant barrier to gene transfer vectors, such as recombinant adeno-associated virus (rAAV). In order to investigate this possibility, aliquots of bronchoalveolar lavage (BAL) fluid from eight individuals with CF were tested for their in vitro inhibitory effects on rAAV transduction, along with BAL from non-CF individuals. While the non-CF BAL fluid was not inhibitory, seven of eight CF BAL samples had significant inhibitory activity, resulting in a five- to 20-fold reduction in transduction events. Inhibition of rAAV transduction by CF BAL could be reversed by alpha-1-antitrypsin (AAT), but not by DNase. When neutrophil elastase and neutrophil alpha defensins (human neutrophil peptides, HNP) were measured in these samples, they were elevated by 500- and 10,000-fold, respectively. The levels of HNP correlated inversely with the amount of rAAV transduction. Furthermore, rAAV transduction could be blocked by purified HNP in an AAT-reversible manner at HNP concentrations within the range measured in these fluids. We conclude that products of inflammation in CF BAL fluid are inhibitory to rAAV transduction, and that these effects may be reversible by AAT.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11083501     DOI: 10.1038/sj.gt.3301268

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  28 in total

Review 1.  Immunological hurdles to lung gene therapy.

Authors:  S Ferrari; U Griesenbach; D M Geddes; E Alton
Journal:  Clin Exp Immunol       Date:  2003-04       Impact factor: 4.330

Review 2.  Virus-based gene delivery systems.

Authors:  Cathryn Mah; Barry J Byrne; Terence R Flotte
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

3.  Postentry processing of recombinant adeno-associated virus type 1 and transduction of the ferret lung are altered by a factor in airway secretions.

Authors:  Ziying Yan; Xingshen Sun; Idil A Evans; Scott R Tyler; Yi Song; Xiaoming Liu; Hongshu Sui; John F Engelhardt
Journal:  Hum Gene Ther       Date:  2013-09       Impact factor: 5.695

Review 4.  Host defense peptides in the oral cavity and the lung: similarities and differences.

Authors:  G Diamond; N Beckloff; L K Ryan
Journal:  J Dent Res       Date:  2008-10       Impact factor: 6.116

5.  Overcoming the cystic fibrosis sputum barrier to leading adeno-associated virus gene therapy vectors.

Authors:  Benjamin S Schuster; Anthony J Kim; Joshua C Kays; Mia M Kanzawa; William B Guggino; Michael P Boyle; Steven M Rowe; Nicholas Muzyczka; Jung Soo Suk; Justin Hanes
Journal:  Mol Ther       Date:  2014-05-29       Impact factor: 11.454

Review 6.  Development of rAAV2-CFTR: History of the First rAAV Vector Product to be Used in Humans.

Authors:  Heather S Loring; Mai K ElMallah; Terence R Flotte
Journal:  Hum Gene Ther Methods       Date:  2016-02-19       Impact factor: 2.396

7.  Modulation of human beta-defensin-1 (hBD-1) in plasmacytoid dendritic cells (PDC), monocytes, and epithelial cells by influenza virus, Herpes simplex virus, and Sendai virus and its possible role in innate immunity.

Authors:  Lisa K Ryan; Jihong Dai; Zhiwei Yin; Nicholas Megjugorac; Victoria Uhlhorn; Sunghan Yim; Kyell D Schwartz; Joshua M Abrahams; Gill Diamond; Patricia Fitzgerald-Bocarsly
Journal:  J Leukoc Biol       Date:  2011-05-06       Impact factor: 4.962

8.  Bronchoalveolar fluid is not a major hindrance to virus-mediated gene therapy in cystic fibrosis.

Authors:  C P Rooney; G M Denning; B P Davis; D M Flaherty; J A Chiorini; J Zabner
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

9.  Insight into the mechanisms of adenovirus capsid disassembly from studies of defensin neutralization.

Authors:  Jason G Smith; Mariena Silvestry; Steffen Lindert; Wuyuan Lu; Glen R Nemerow; Phoebe L Stewart
Journal:  PLoS Pathog       Date:  2010-06-24       Impact factor: 6.823

10.  In vitro and in vivo functional characterization of gutless recombinant SV40-derived CFTR vectors.

Authors:  C Mueller; M S Strayer; J Sirninger; S Braag; F Branco; J-P Louboutin; T R Flotte; D S Strayer
Journal:  Gene Ther       Date:  2009-11-05       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.